[Cholestasis-induced liver injury: the role of S1PR2].

Med Sci (Paris)

Équipe interactions cellulaires et physiopathologie hépatique (ICPH), Inserm UMR S1174, Université Paris-Saclay, bâtiments 440-443, rue des Adèles, 91400 Orsay, France.

Published: April 2019

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20173306016DOI Listing

Publication Analysis

Top Keywords

[cholestasis-induced liver
4
liver injury
4
injury role
4
role s1pr2]
4
[cholestasis-induced
1
injury
1
role
1
s1pr2]
1

Similar Publications

Lipopolysaccharide (LPS) causes inflammatory cholestasis in sepsis. We investigated the role of PDZK1 in the repression of ABC transporters in LPS-induced cholestasis. Lentiviral gene transfer of PDZK1 to rats was conducted to explore its influence on cholestasis induced by LPS.

View Article and Find Full Text PDF
Article Synopsis
  • - Cholestatic liver diseases (CLD) cause damage to the liver cells and can lead to fibrosis and cirrhosis due to bile acid accumulation, with STARD1 playing a potential role in this process.
  • - Research found that patients with primary biliary cholangitis had higher STARD1 levels, and mice lacking STARD1 specifically in liver cells were more resistant to liver damage and inflammation associated with bile duct blockage.
  • - The study suggests that targeting STARD1 could be a promising approach for treating cholestatic liver injury, as it appears to influence bile acid levels and oxidative stress in liver cells.
View Article and Find Full Text PDF

Contradictory results have been reported about the effects of liver diseases on the blood-brain barrier (BBB) permeability to markers. For instance, both an increase and no change in the BBB permeability to BBB markers sodium fluorescein and Evans blue have been reported in experimental cholestasis induced by bile duct ligation (BDL) in rats. These contradictory effects might be due to inherent limitations of these markers and/or methodological issues.

View Article and Find Full Text PDF
Article Synopsis
  • Swertia cincta is a traditional remedy used in Yunnan, China, for treating cholestasis, although its active components and mechanisms are not well understood.
  • The study aimed to investigate the therapeutic properties and active ingredients of Swertia cincta using an animal model of cholestasis induced by alpha-naphthylisothiocyanate (ANIT).
  • Results revealed that specific components like gentiopicroside, loganic acid, and isoorientin help regulate various liver-related proteins and reduce inflammation, enhancing the liver's protective response against cholestatic injury.
View Article and Find Full Text PDF

Cholestasis refers to a physiological and pathological process caused by bile acid (BA) overaccumulation inside the circulatory system and liver, leading to systemic and hepatocellular damage. Activating the farnesol X receptor (FXR) to restore BA homeostasis is a promising strategy for treating cholestasis. The objective of this research is to reveal solid evidence for the fact that the total iridoid glycosides from Franch.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!